[go: up one dir, main page]

AR048318A1 - Formulaciones de matriz orales que comprenden licarbazepina - Google Patents

Formulaciones de matriz orales que comprenden licarbazepina

Info

Publication number
AR048318A1
AR048318A1 ARP050101070A ARP050101070A AR048318A1 AR 048318 A1 AR048318 A1 AR 048318A1 AR P050101070 A ARP050101070 A AR P050101070A AR P050101070 A ARP050101070 A AR P050101070A AR 048318 A1 AR048318 A1 AR 048318A1
Authority
AR
Argentina
Prior art keywords
licarbazepine
licarbazepina
matrix formulations
oral
oral matrix
Prior art date
Application number
ARP050101070A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0406379A external-priority patent/GB0406379D0/en
Priority claimed from GB0406738A external-priority patent/GB0406738D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR048318A1 publication Critical patent/AR048318A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Una composicion farmacéutica oral de liberacion controlada, la cual comprende 10,11-dihidro-10-hidroxi-5H-dibenz[b,f]azepin-5-carboxamida (licarbazepina). Reivindicacion 13: El uso de licarbazepina y excipienets como se definen en cualquiera de las reivindicaciones 1 a 12, para la preparacion de un medicamento para el ratamiento de pacientes con desordenes afectivos. Reivindicacion 14: Un método para la administracion oral de licarbazepina, por ejemplo para el tratamiento de desordenes afectivos, comprendiendo este método administrar oralmente a un paciente que necesite terapia con licarbazepina una vez al día, una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 12.
ARP050101070A 2004-03-22 2005-03-18 Formulaciones de matriz orales que comprenden licarbazepina AR048318A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0406379A GB0406379D0 (en) 2004-03-22 2004-03-22 Organic compounds
GB0406738A GB0406738D0 (en) 2004-03-25 2004-03-25 Organic compounds

Publications (1)

Publication Number Publication Date
AR048318A1 true AR048318A1 (es) 2006-04-19

Family

ID=34961345

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101070A AR048318A1 (es) 2004-03-22 2005-03-18 Formulaciones de matriz orales que comprenden licarbazepina

Country Status (16)

Country Link
US (1) US20070196488A1 (es)
EP (1) EP1732519A1 (es)
JP (1) JP2007529564A (es)
AR (1) AR048318A1 (es)
AU (1) AU2005226910B2 (es)
BR (1) BRPI0509067A (es)
CA (1) CA2558787A1 (es)
EC (1) ECSP066860A (es)
IL (1) IL177826A0 (es)
MA (1) MA28527B1 (es)
MX (1) MXPA06010810A (es)
NO (1) NO20064808L (es)
PE (1) PE20051156A1 (es)
RU (1) RU2006137330A (es)
TW (1) TW200534844A (es)
WO (1) WO2005092294A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
EP2380574A1 (en) * 2005-05-06 2011-10-26 Bial-Portela & CA, S.A. Eslicarbazepine acetate and methods of use
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) * 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
US9346760B2 (en) 2011-03-08 2016-05-24 Jubilant Life Sciences Limited Process for the preparation of (S)-(+)- or (R)-(-)-10-hydroxy dihydrodibenz[B,F]azepines by enantioselective reduction of 10,11-dihydro-10-OXO-5H-dibenz[B,F]azepines and polymorphs thereof
EP2498481A1 (en) 2011-03-09 2012-09-12 Sensirion AG Mobile phone with humidity sensor
JP2013237676A (ja) * 2013-06-26 2013-11-28 Bial-Portela & Ca Sa 酢酸エスリカルバゼピン及び使用方法
HUE057788T2 (hu) 2015-12-18 2022-06-28 Jubilant Generics Ltd Eslikarbazepin szilárd orális dózisformái

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
IL125244A (en) * 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
MXPA04011801A (es) * 2002-05-31 2005-09-12 Desitin Arzneimittel Gmbh Composicion farmaceutica que contiene oxcarbazepina con liberacion controlada de la substancia activa.
EP1528927A1 (en) * 2002-08-06 2005-05-11 Novartis AG Use of carboxamides for the treatment of tinnitus
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina

Also Published As

Publication number Publication date
AU2005226910B2 (en) 2009-06-04
EP1732519A1 (en) 2006-12-20
ECSP066860A (es) 2006-11-24
PE20051156A1 (es) 2006-02-13
WO2005092294A1 (en) 2005-10-06
AU2005226910A1 (en) 2005-10-06
RU2006137330A (ru) 2008-05-10
JP2007529564A (ja) 2007-10-25
US20070196488A1 (en) 2007-08-23
TW200534844A (en) 2005-11-01
CA2558787A1 (en) 2005-10-06
NO20064808L (no) 2006-12-15
MA28527B1 (fr) 2007-04-03
MXPA06010810A (es) 2006-12-15
BRPI0509067A (pt) 2007-08-21
IL177826A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
AR048705A1 (es) Composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
AR043467A1 (es) Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
ECSP078023A (es) Ingrediente farmacéutico activo en base a canabinoide
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
EP2248519A3 (en) Non-mucoadhesive film dosage forms
PT1173178E (pt) Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil
AR065731A1 (es) Composiciones farmaceuticas que contienen 2-[6-(3-amino-pipenidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-primidin-1-il metil]-4-fluoro-benzonitrilo. uso. metodo de tratamiento, administracion semanal de inhibidores de la dipeptidilpeptidasa.
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
AR056824A1 (es) Tableta de neramexano con matriz de liberacion modificada
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
TW200501945A (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
AR054249A1 (es) Tratamiento de enfermedades del tejido conectivo de la piel
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure